Vaccines and Immune Therapies
We are committed to developing and delivering transformative vaccines and antibodies, providing long lasting immunity for millions of people, where the burden of disease is greatest. During the COVID-19 pandemic, we played an important role as part of a truly global effort to respond to a new and unprecedented challenge.1 We will continue to advance science in vaccines and immune therapies and work with partners to drive improvements in public health and ensure our science reaches millions more people.
Looking to the future
Imagine a world where a single vaccine could protect people against coronavirus, flu, and respiratory syncytial virus. A world where long-acting antibodies protect the most vulnerable against those same infectious diseases, for more than a year. This is the future we are working towards.
Our focus areas
To achieve our ambition, we are optimising the potential of both vaccines and antibodies to ensure no patient is left behind. We are engineering next generation vaccines that have the potential to generate potent and long-lasting immune responses. At the same time, we are pioneering novel approaches to develop highly targeted, long-acting antibodies, optimised with our half-life extension technology.2 We focus on a range of pathogens, including SARS-CoV-2,3 influenza4 and RSV.5
Vaccines for active immunisation; antibodies for passive immunisation for those who can’t mount an immune response
Innovative next-generation technologies for vaccines; accelerated human antibody discovery, long acting, high-yield manufacturing for antibodies.
SAR-CoV-2, influenza, RSV & beyond
We are a passionate and dedicated team of scientists, researchers, clinicians, medical and commercial professionals. We are breaking new boundaries with our discoveries, supported by our heritage, and empowered by our collaborations with commercial, academic and government leaders across the world.
The Vaccines and Immune Therapies unit is at the forefront of a new and exciting era of disease prevention. I am inspired by our team’s dedication to pushing the boundaries of science, helping to create a fairer and healthier future for all.
We cannot provide detailed information about our prescription medicines on this website, in compliance with regulations. Our medicines are approved in individual countries for specific uses and the information we provide for patients is governed by local regulations. In some cases, health care professionals and patients can visit local AstraZeneca websites to find out more about our medicines. Please note that in some countries we are not allowed to provide very much, or sometimes any, information on our prescription medicines so you should seek alternative trustworthy sources. Always ask a healthcare professional for advice about medicines.
tixagevimab and cilgavimab
Fluenz Tetra/FluMist Quadrivalent
influenza vaccine live, intra-nasal
Our pipeline for V&I
We are passionate about pushing the boundaries of science, developing next generation vaccines and antibodies that have the power to transform the way we prevent and treat endemic and pandemic viruses.
1. AstraZeneca. Vaxzevria shown in expert review to provide equally effective protection against COVID-19 hospitalisation and death as mRNA vaccines [Last accessed: October 2022]. Available from: http://1l.szzhuodong.com/media-centre/medical-releases/vaxzevria-shown-in-expert-review-to-provide-equally-effective-protection-against-covid-19.html.
2. AstraZeneca news release. COVID-19 Long-Acting AntiBody (LAAB) Combination AZD7442 Rapidly Advances into Phase III Clinical Trials.: Last accessed: October 2022. Available from: http://1l.szzhuodong.com/media-centre/press-releases/2020/covid-19-long-acting-antibody-laab-combination-azd7442-rapidly-advances-into-phase-iii-clinical-trials.html.
3. Voysey M et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 2021; 397(10277):881–91.
4. ClinicalTrials.gov. Clinical Use of EVUSHELD as Pre-exposure Prophylaxis in Real-world Setting in Gulf Cooperation Council Countries (EVOLVE): Last accessed: October 2022. Available from: http://clinicaltrials.gov/ct2/show/NCT05315323.
5. ClinicalTrials.gov. A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Late Preterm and Term Infants (MELODY) [Last accessed: October 2022]. Available from: http://clinicaltrials.gov/ct2/show/NCT03979313
Veeva ID: Z4-49108
Date of preparation: October 2022